Search
for
Sort by
Research 31–60 of 1000+
- Alopecia – New building blocks
- Revisión y avances en tricología
- Efficacy and safety of baricitinib in patients with refractory alopecia areata
- Baricitinib for alopecia areata
- Two phase III trials of baricitinib for alopecia areata: a critically appraised research paper
- Two Phase 3 Trials of Baricitinib for Alopecia Areata
- Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
- Baricitinib (Olumiant)
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- Use of Jak Inhibitors in the Treatment of Alopecia Areata
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- Journal of Population Therapeutics and Clinical Pharmacology
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Deuruxolitinib for Alopecia Areata.
- Emerging drugs for the treatment of alopecia areata
- Baricitinib-loaded separable microneedle array patch (S-MAP) based on hyaluronic acid for alopecia areata therapy
- Hair Loss in an 11-year-old
- Baricitinib-loaded EVs promote alopecia areata mouse hair regrowth by reducing JAK-STAT-mediated inflammation and promoting hair follicle regeneration
- Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study
- Baricitinib: A Review in Severe Alopecia Areata